Should You Stop Probiotics During SIBO Treatment?

Ask ten SIBO specialists whether to continue probiotics during antibiotic treatment and you'll get a range of confident, sometimes contradictory answers. Some say stop them immediately: you're trying to reduce bacterial load, and adding more bacteria is working against your treatment. Others say continue specific strains throughout: the benefits outweigh the risks, and certain probiotics actively support treatment outcomes. A third camp distinguishes carefully between strains and says the question can't be answered in the abstract. All three positions have some evidence behind them. This article examines what the research actually shows, identifies the most important exception (Saccharomyces boulardii), and gives you a practical framework for making the decision with your provider.

The Case for Stopping Probiotics During Treatment

The argument for stopping probiotics during SIBO treatment is intuitive and mechanistically grounded. SIBO is, by definition, bacterial overgrowth — too many bacteria in the wrong place. The entire goal of treatment with rifaximin, neomycin, or herbal antimicrobials is to reduce that bacterial load in the small intestine. Introducing billions of additional live bacteria through a probiotic supplement during this process seems counterproductive: you are adding to what you're trying to reduce.

The 2018 Rao study on probiotics and D-lactic acidosis is frequently cited in this context. That research found that some patients — particularly those taking Lactobacillus-dominant probiotics — had significant symptom worsening, brain fog, and elevated D-lactic acid levels. Many of these patients improved when probiotics were stopped. While the study specifically concerned the D-lactic acidosis mechanism, it reinforced the principle that probiotics are not universally safe or beneficial in the context of small intestinal bacterial dysbiosis.

There is also a practical concern about probiotic bacteria surviving treatment. Rifaximin is minimally absorbed systemically and acts primarily in the gut lumen. Some probiotic organisms — particularly spore-forming strains — are highly resistant to antibiotics. If probiotic bacteria colonize the small intestine during treatment, they may simply repopulate it after the antibiotic course ends, potentially contributing to a recurrence pattern.

The Case for Continuing Specific Strains

The argument for continuing probiotics during SIBO treatment isn't simply reflexive enthusiasm for gut bacteria — it rests on specific mechanisms and specific strains. Antibiotic treatment, even gut-targeted rifaximin, does not leave the intestinal microbiome untouched. Studies have shown that rifaximin can reduce populations of Bifidobacterium and Lactobacillus in the colon, altering the microbiome even though it is marketed as gut-selective. Neomycin has broader effects. Concurrent probiotic use may help maintain or restore colonic microbial diversity during treatment, reducing the risk of opportunistic pathogen overgrowth.

A specific concern with any antibiotic treatment is the risk of Clostridioides difficile (C. diff) infection — a serious intestinal infection that can result from antibiotic disruption of the normal microbial community. Multiple systematic reviews and meta-analyses have found that Saccharomyces boulardii and certain Lactobacillus strains reduce the incidence of C. diff-associated diarrhea when taken alongside antibiotics. For this reason, many gastroenterologists who are cautious about probiotics generally will still recommend S. boulardii specifically during antibiotic courses.

The Saccharomyces Boulardii Exception

Saccharomyces boulardii deserves its own discussion because it is categorically different from bacterial probiotics — it is a yeast, specifically a tropical strain of Saccharomyces cerevisiae. As a yeast, S. boulardii is fundamentally unaffected by antibacterial treatments including rifaximin and neomycin. It cannot be killed by antibiotics targeting bacterial cell walls, ribosomes, or DNA replication. This means that unlike bacterial probiotics, S. boulardii can remain active and effective throughout an antibiotic course without being eliminated.

S. boulardii does not contribute to D-lactic acidosis (it produces L-lactic acid, which humans metabolize normally, and does not produce D-lactic acid). It does not add to bacterial overgrowth in the small intestine because it is not a bacterium. Its documented mechanisms include: secreting proteases that degrade bacterial toxins (including C. diff toxins A and B), stimulating secretory IgA production in the intestinal mucosa, reducing intestinal inflammation, and competing with pathogenic bacteria and fungi for colonization sites.

What the Research Shows: Current Evidence Summary

The honest summary of the research is that we don't have large, well-designed randomized controlled trials specifically examining probiotic use during SIBO antibiotic treatment in terms of treatment outcomes (eradication rates, symptom resolution, recurrence rates). The recommendations practitioners make are based on mechanistic reasoning, extrapolation from adjacent literature (antibiotic-associated diarrhea prevention, IBD management, post-antibiotic microbiome recovery), and clinical experience.

What we do have: clear evidence that S. boulardii reduces antibiotic-associated diarrhea and C. diff risk; clear evidence that Lactobacillus-dominant probiotics can worsen some SIBO presentations (Rao 2018); a theoretical concern about probiotic bacteria colonizing the small intestine during SIBO treatment; and clinical practice patterns suggesting that most experienced SIBO practitioners recommend stopping Lactobacillus-dominant probiotics while maintaining S. boulardii and optionally Bifidobacterium-based products.

Timing: If You Do Use Probiotics, When?

For bacterial probiotics taken alongside antibiotics, timing matters. Rifaximin and neomycin, even though they are poorly absorbed, are most concentrated in the gut lumen for several hours after each dose. Taking bacterial probiotics within two hours of an antibiotic dose may reduce probiotic survival. If you and your provider decide to continue a bacterial probiotic during treatment, taking it at least two hours away from each antibiotic dose — or timing doses at the end of the day after antibiotics are taken in the morning — may improve probiotic viability.

S. boulardii does not require this separation because it is unaffected by antibacterial treatment and can be taken at any time. Post-treatment, the recommendation is to begin or resume a comprehensive probiotic regimen — including Bifidobacterium and selected Lactobacillus strains — two to four weeks after completing the antibiotic course, with the goal of rebuilding microbiome diversity and reducing the risk of SIBO recurrence.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.